Read the finding with its limits attached.
Here's the reading behind the guide. Some papers follow hormone signals, others measure outcomes in people. The FDA sources explain safety and approval. A source is most useful when we keep its question beside its finding.
Ipamorelin and the difference between signal and outcome
- Ipamorelin in early cell and animal tests
Raun and colleagues, 1998. The experiments found a selective growth-hormone response. They did not test sleep or everyday recovery in people.
- The human ipamorelin hormone study
Gobburu and colleagues, 1999. Healthy men received intravenous ipamorelin. The study followed drug levels and a short growth-hormone burst, rather than sleep or recovery.
- Ipamorelin after bowel surgery
Beck and colleagues, 2014. The trial missed its main goal of showing earlier meal tolerance. That result matters, even when the idea behind a treatment sounds plausible.
- FDA's review of ipamorelin
FDA, 2024. This review describes the human studies and gaps in basic safety testing. It also raises concerns about possible immune reactions to injected preparations.
CJC-1295 and the exact form tested
- The long-acting CJC-1295 human study
Teichman and colleagues, 2006. Growth hormone and IGF-1 stayed raised for days. That finding belongs to the long-acting form tested, rather than any proposed mixture.
- Growth-hormone bursts during CJC-1295 stimulation
Ionescu and Frohman, 2006. Hormone bursts continued during longer stimulation. This tells us about the pattern of release, rather than the benefit of adding another peptide.
- FDA's review of CJC-1295 forms and risks
FDA, 2024. The review distinguishes related forms and flags confusing names. It discusses adverse reactions, possible immune responses and unknown long-term safety.
Tirzepatide, BPC-157 and the safety context
- Tirzepatide in a weight-management trial
Jastreboff and colleagues, 2022. Adults taking tirzepatide lost more weight on average than those taking placebo. The trial did not test adding the other peptides discussed here.
- Tirzepatide weight-management prescribing information
The U.S. label describes the approved product, its uses, warnings and interactions. It supplies safety context that an average trial result cannot give on its own.
- BPC-157 and musculoskeletal healing
McGuire and colleagues, 2025. This review describes extremely limited human evidence alongside the animal research. It calls for stronger studies before treating repair claims as established.
- The two-person BPC-157 safety pilot
Lee and Burgess, 2025. This intravenous pilot reported no adverse events in two adults. It did not test injury healing and cannot establish long-term safety.
- BPC-157 and new blood-vessel growth
Hsieh and colleagues, 2017. Cell and animal experiments explored effects on vessel growth. Those findings help explain the repair idea without proving that people heal faster.
- FDA's bulk-substance safety page
The page current as of April 22, 2026 separates Category 2 from withdrawn nominations. The requests were taken back, but FDA still records the safety worries.
- FDA's explanation of compounded-drug risks
Compounded medicines have no FDA approval, as this FDA explanation makes clear. An approved active ingredient doesn't make a different preparation or an added ingredient approved.
Read for the result you care about.
Who received what, what changed, and was the proposed pairing actually tested?